6 completed. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
Follow Xspray Pharma AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions. XS003 (nilotinib), Tasigna (nilotinib) - Cancer | Phase 1 | Completed | Xspray Pharma AB | 128 | 2024-11-15 | 2025-08-22 |
| Bioavailability Study of XS003 (Nilotinib) XS003 under fed and fasted condition - Cancer | Phase 1 | Completed | Xspray Pharma AB | 48 | 2024-10-03 | 2025-08-22 |
| An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL® SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg - Drug-drug Interaction Study | Phase 1 | Completed | Xspray Pharma AB | 18 | 2023-08-22 | 2023-11-24 |
| Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions Dasatinib ASD 100 mg, Dasatinib 140 MG [Sprycel] - Biological Availability | Phase 1 | Completed | Xspray Pharma AB | 110 | 2021-06-07 | 2022-06-30 |
| Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions Dasatinib ASD, Omeprazole 40 MG - Pharmacokinetics, Drug Interactions | Phase 1 | Completed | Xspray Pharma AB | 17 | 2020-11-01 | 2022-06-27 |
| Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects Sorafenib - Period 1, XS005 Sorafenib Capsule A - Period 1, XS005 Sorafenib Tablet A - Period 1 - Pharmacokinetics, Bioavailability | Phase 1 | Completed | Xspray Pharma AB | 15 | 2018-11-16 | 2023-08-01 |
Neoplasms (2)
Dasatinib (2) · Omeprazole (1) · Regimen B (1) · nilotinib (1)
India (3) · United States (2) · United Kingdom (1)
Maria Klockare (3) · Per Andersson, PhD (2) · Sharan Sidhu, MBChB, BAO, MRCS, MFPM (1)